In this episode, we explore the safety of antipsychotics in patients with liver disease. How can psychiatrists navigate the risk–benefit balance when treating medically complex individuals? Dr. Sydney LeFay discusses key insights from a recent review article, guiding antipsychotic selection and monitoring.

Faculty: Sydney LeFay, D.O. Host: Richard Seeber, M.D.

• Learn more about our membership here
• Earn 0.75 CMEs: Quick Take Vol. 56
• Antipsychotic Safety in Liver Disease